Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In updated ...

Researchers assessed disparities in COPD clinical trial participation based on gender, COPD severity, and geography and evaluated gender representation among researchers.

The Food and Drug Administration (FDA) has accepted an application for Priority Review for dupilumab as an add-on therapy for adults with uncontrolled chronic obstructive pulmonary disease (COPD), ...

(RTTNews) - The U.S. Food and Drug Administration has extended by three months the target action date of its priority review of the supplemental Biologics License Application or sBLA for Dupixent ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for mepolizumab as an add-on maintenance treatment for chronic obstructive pulmonary disease ...

Findings from BOREAS and NOTUS showed dupilumab significantly reduced moderate to severe acute COPD exacerbations vs placebo. The Food and Drug Administration (FDA) has accepted for Priority Review ...

For patients with chronic obstructive pulmonary disease, healing from home may be as good as receiving treatment in hospital, according to new research. “We know that pulmonary rehab is a highly ...

Discussions will cover new guidelines for noninvasive ventilation in COPD, focusing on challenges and practical implementation.

Please provide your email address to receive an email when new articles are posted on . The FDA has accepted to review a supplemental new drug application for mepolizumab, an anti-IL-5 biologic, for ...

In this micro-activity, learners will engage with a 15-minute expert faculty podcast focused on the latest advancements in COPD management and novel therapeutics. Accompanying the podcast is an ...